What is BNCT

Transcription

What is BNCT

What is BNCT ?
y Boron Neutron Capture Therapy
y two phase experimental cancer radiation treatment
y the effectiveness of BNCT depends on the boron-10
concentration within the cell
Katariina Kortelainen
ISRRT
Durban 2008
y boron is given to the patient in iv
y it takes 2 hours to give the boron
y boron carrier compound takes the boron to right target
y this way it is possible to deliver high concentrations of boron to
the tumor relative to the surrounding normal tissues
4 May 2008
1
4 May 2008
2
BNCT in Finland
BNCT in Finland
y first brain tumor treatment given in May 1999 to
y first head/neck treatment given in December 2003
y BNCT is given jointly by
y the Department of
Oncology
y Helsinki University
Central Hospital
y Boneca Corporation
y in the world total given treatments 350
y 1/3 treatments given in Finland – total 121
y brain tumors treated 49
y head/neck tumors treated 78
y patients from all over Finland and from Europe
4 May 2008
VTT Technical Research Centre of Finland
3
Schematic presentation of
BNCT treatment
4 May 2008
4
BNCT delivery
y entire BNCT treatment
procedure takes from five
to seven days
y days 1 and 2 (treatment
planning)
y
y
y
y
doctors appointment
a written informed consent
for participation in BNCT
laboratory tests
tumor size evaluation and
location
y
MRI, CT and PET
Simulation room at VTT
From: Boneca Oy
4 May 2008
5
4 May 2008
6
BNCT delivery
BNCT delivery
y days 3 to 7 (treatment and
y prior to irradiation, the boron carrier (BPA) will be given
as a 2-hour infusion into a peripheral vein
y boron level is checked frecguently by blood samples to
ensure right borol levels
y treatment time is based on boron levels
y once the boron infusion has been completed, the patient is
positioned for neutron irradiation
y the irradiation is usually given from two directions to the
tumor site
y each one of these irradiations takes about 20-30 minutes
follow-up)
y
y
y
y
y
y
medication
patient positioning day
before BNCT treatment
boron carrier (BPA) will be
given as a 2-hour infusion
into a peripheral vein
blood samples
irradiation
follow-up at the hospital
usually lasts for about 2-3
days
4 May 2008
Treatment room at VTT
7
4 May 2008
8
9
4 May 2008
10
Patient positioning and fixation
for BNCT
y positioning in BNCT differs considerably from the
conventional radiation therapy positioning
y BNCT the positioning system has to facilitate the multiple
static fields and close aperture contact to the patient
during the irradiation
y in brain treatments the distance is only 1 cm
y the patient - instead of the beam - has to be set into proper
position and alignment for the treatment
y in BNCT treatment you needs to find the entry and exit
point
4 May 2008
Enrty point visualized in
simulation room
Patient positioning and fixation
for BNCT
y positioning of the patient is divided into two sessions
y the first session;
y
the patient position and fixation is prepared in the simulation
room according to the co-ordinates
y the second session (during the actual treatment);
y
4 May 2008
the patient is set to this predefined position using the positioning
lasers and precise 3D movements of the positioning system
11
4 May 2008
12
BNCT equipment
y the mobile treatment table with docking ability, controlled
3D movements and the attached head support
y the mobile beam simulator for use in the simulation room
y radiation therapy vacuum cushions and tapes are needed
for the fixation of the head. The patient body position is
supported comfortably with large vacuum cushions and
soft fleece mattresses
4 May 2008
13
4 May 2008
14
Radiographers role in BNCT
y First day
y entry and exit point are marked according to planning
cordinates
y simulate the treatment
y positioning to the treatment fields
y patient fixations are made and ensured
y Second day
y position the patient as simulated one day before
4 May 2008
15
4 May 2008
16
4 May 2008
17
4 May 2008
18
4 May 2008
19
4 May 2008
20
4 May 2008
21
4 May 2008
22
Our mutilprofessional BNCT team
For who BNCT
y who have primary glioblastoma; glioblastoma or anaplastic
y
y
y
y
4 May 2008
www.boneca.fi
23
astrocytoma that has recurred following conventional
treatment
head and neck cancer that has recurred loco regionally
following conventional treatment
whose general condition is good or moderate
whose tumor size and tumor site are compatible with BNCT
who have no effective standard treatment options available
4 May 2008
24
4 May 2008
25

What is BNCT

Transcription

Similar documents

Exsanguination - Northern Health

The Myelin Sheath

AMPULLA OF VATER STAGING FORM

Evolutionary optimization in (deformable) registration of medical

Course Brochure

Full text in pdf format

Tumor Antigens and Cancer Vaccines

tumor marker`s

The Great Indoors: Challenges and Use Cases

Abstract Book with detailed program

pdf-file